The cryptocurrency-funded peptide market has surpassed a $100 million annual run rate after first-quarter sales jumped 159% quarter-over-quarter to $32 million, according to a new report from Chainalysis.
Summary
- Chainalysis says the crypto-funded peptide market has exceeded a $100 million annual run rate.
- Q1 2026 peptide sales jumped 159% quarter-over-quarter to $32 million.
- Average spending on independent purity testing fell 88% per buyer, raising safety concerns as demand for peptides continues to grow.
According to Chainalysis, demand for off-label peptides has expanded rapidly beyond niche biohacking communities, creating a growing gray-market industry that increasingly relies on cryptocurrency payments.
The blockchain analytics firm said peptide purchases reached $32 million during the first quarter of 2026, up from $12 million in the previous quarter.
Peptides, which are short chains of amino acids used in health, fitness, and wellness products, have gained attention following the success of GLP-1 drugs such as Ozempic and Wegovy. Chainalysis said growing consumer interest in weight loss, performance enhancement, and recovery products has pushed more buyers toward alternative peptide suppliers operating outside traditional pharmaceutical channels.
Many of those suppliers are based in China, where access to conventional banking services can be limited for businesses selling prescription-grade compounds and unregulated substances. As a result, Chainalysis said cryptocurrency has become a key payment rail connecting manufacturers with international buyers.
Stablecoins have become the preferred payment method
Examining on-chain activity linked to major peptide vendors, Chainalysis found that larger suppliers increasingly favor stablecoins over more volatile cryptocurrencies.
The firm said vendors receiving average deposits of at least $1,000 showed a payment mix dominated by stablecoins, suggesting an effort to reduce exposure to crypto price swings while handling larger supply-chain transactions.
What began as a small market catering to specialized buyers has evolved into a more organized ecosystem, according to Chainalysis.
The report noted that leading vendors are adopting increasingly sophisticated on-chain financial practices while continuing to process significant volumes through Bitcoin and stablecoins.
Chainalysis compared the peptide trade to other gray-market industries that have historically turned to cryptocurrency after encountering restrictions from banks and payment processors. The firm said suppliers can offer raw and unbranded products directly to consumers at prices well below those available through regulated channels.
The findings also fit into a wider trend previously identified by Chainalysis. Earlier this year, the company reported that cryptocurrency flows to suspected trafficking services rose 85% during 2025, with stablecoin-heavy networks operating through Telegram and other online platforms.
Chainalysis said blockchain transparency nevertheless provides investigators with permanent transaction records that can help track financial activity and identify key intermediaries.
Quality testing spending has fallen despite rising demand
Alongside rising sales, Chainalysis identified a decline in spending on independent product testing among peptide buyers.
The firm said many customers previously sent payments both to peptide suppliers and to Janoshik, a Czech-based laboratory that tests chemical purity. As the number of buyers surged, however, testing expenditures failed to keep pace with sales growth.
According to Chainalysis estimates, average testing spending per buyer fell 88% to roughly $8, even though Janoshik is conducting more tests than before. The decline occurred because new demand entered the market faster than testing activity expanded.
Safety concerns have also emerged around some suppliers participating in the industry. Chainalysis reported that Shanghai Sigma Audley, a company it linked to organizations previously involved in selling fentanyl precursors, generated at least $1 million in Bitcoin and $3.59 million in stablecoins before expanding into peptide sales.
Given the combination of unregulated products and cryptocurrency-based transactions, Chainalysis warned that many new customers entering the sector may have limited experience with either market, increasing potential risks as the industry continues to grow.
